- Home
- IFN vs PRAX Comparison
IFN vs PRAX Comparison
Compare IFN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFN
- PRAX
- Stock Information
- Founded
- IFN 1993
- PRAX 2015
- Country
- IFN Singapore
- PRAX United States
- Employees
- IFN N/A
- PRAX N/A
- Industry
- IFN Finance/Investors Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- IFN Finance
- PRAX Health Care
- Exchange
- IFN Nasdaq
- PRAX Nasdaq
- Market Cap
- IFN 560.2M
- PRAX 599.7M
- IPO Year
- IFN N/A
- PRAX 2020
- Fundamental
- Price
- IFN $16.28
- PRAX $41.20
- Analyst Decision
- IFN
- PRAX Strong Buy
- Analyst Count
- IFN 0
- PRAX 11
- Target Price
- IFN N/A
- PRAX $114.73
- AVG Volume (30 Days)
- IFN 135.2K
- PRAX 290.8K
- Earning Date
- IFN 01-01-0001
- PRAX 05-02-2025
- Dividend Yield
- IFN 8.68%
- PRAX N/A
- EPS Growth
- IFN N/A
- PRAX N/A
- EPS
- IFN N/A
- PRAX N/A
- Revenue
- IFN N/A
- PRAX $8,122,000.00
- Revenue This Year
- IFN N/A
- PRAX N/A
- Revenue Next Year
- IFN N/A
- PRAX N/A
- P/E Ratio
- IFN N/A
- PRAX N/A
- Revenue Growth
- IFN N/A
- PRAX 270.02
- 52 Week Low
- IFN $14.40
- PRAX $26.70
- 52 Week High
- IFN $21.25
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- IFN 52.83
- PRAX 61.52
- Support Level
- IFN $16.22
- PRAX $36.30
- Resistance Level
- IFN $16.48
- PRAX $38.90
- Average True Range (ATR)
- IFN 0.18
- PRAX 2.18
- MACD
- IFN -0.06
- PRAX 0.32
- Stochastic Oscillator
- IFN 24.72
- PRAX 98.84
About IFN India Fund Inc. (The)
India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing primarily in the equity securities of Indian companies. The company's portfolio is non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities and others. Geographically, all the business activity functions through the market of United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.